https://wikimd.org/index.php?action=history&feed=atom&title=VVD-118313VVD-118313 - Revision history2026-04-28T12:26:34ZRevision history for this page on the wikiMediaWiki 1.44.2https://wikimd.org/index.php?title=VVD-118313&diff=6428464&oldid=prevPrab: CSV import2025-03-05T06:35:13Z<p>CSV import</p>
<p><b>New page</b></p><div>{{Short description|Overview of the experimental drug VVD-118313}}<br />
<br />
==VVD-118313==<br />
[[File:VVD-118313_structure.png|Structure of VVD-118313|thumb|right]]<br />
'''VVD-118313''' is an experimental drug that has been investigated for its potential therapeutic effects in the treatment of various neurological disorders. It is a small molecule that acts as a selective antagonist of the [[5-HT6 receptor]], a subtype of the [[serotonin receptor]] family. The compound was developed with the aim of improving cognitive function and has been studied primarily in the context of [[Alzheimer's disease]] and other forms of [[dementia]].<br />
<br />
==Pharmacology==<br />
VVD-118313 functions by selectively binding to and inhibiting the activity of the 5-HT6 receptor. This receptor is predominantly expressed in the [[central nervous system]], particularly in regions of the brain associated with learning and memory, such as the [[hippocampus]] and [[cortex]]. By blocking the 5-HT6 receptor, VVD-118313 is thought to enhance the release of neurotransmitters like [[acetylcholine]], [[dopamine]], and [[glutamate]], which play crucial roles in cognitive processes.<br />
<br />
==Mechanism of Action==<br />
The 5-HT6 receptor is a [[G protein-coupled receptor]] (GPCR) that is positively coupled to [[adenylate cyclase]], leading to an increase in [[cyclic AMP]] (cAMP) levels when activated. By antagonizing this receptor, VVD-118313 reduces cAMP production, which in turn modulates neurotransmitter release and neuronal signaling pathways. This modulation is believed to contribute to the cognitive-enhancing effects observed in preclinical studies.<br />
<br />
==Potential Therapeutic Applications==<br />
VVD-118313 has been primarily investigated for its potential use in treating cognitive deficits associated with [[Alzheimer's disease]]. Preclinical studies have shown that the compound can improve performance in animal models of memory impairment. Additionally, there is interest in exploring its use in other conditions characterized by cognitive dysfunction, such as [[schizophrenia]] and [[Parkinson's disease]].<br />
<br />
==Development and Research==<br />
The development of VVD-118313 is part of a broader effort to create novel treatments for cognitive disorders by targeting the serotonergic system. While the compound has shown promise in early-stage research, further studies are needed to fully understand its efficacy and safety profile in humans. Clinical trials are necessary to determine the optimal dosing, potential side effects, and long-term benefits of VVD-118313.<br />
<br />
==Related pages==<br />
* [[5-HT6 receptor]]<br />
* [[Serotonin receptor]]<br />
* [[Alzheimer's disease]]<br />
* [[Cognitive enhancement]]<br />
<br />
[[Category:Experimental drugs]]<br />
[[Category:Serotonin antagonists]]<br />
[[Category:Neuropharmacology]]</div>Prab